New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2, R.sup.2 represents the radical of the formula ##STR3## wherein R.sup.3 is selected from the group consisting of (a) H (b) alkyl groups containing 1-3 carbon atoms ##STR4## wherein R.sup.5 is selected from the group consisting of (e) OH (b) alkoxy groups containing 1-3 carbon atoms and wherein R.sup.4 is selected from the group consisting of (a) H (b) alkyl groups containing 1-3 carbon atoms, with the proviso that R.sup.3 and R.sup.4 are combined as follows: ______________________________________ when R.sup.3 is then is R.sup.4 ______________________________________ H H alkyl group of 1-3 carbon atoms H or an alkyl group of 1-3 carbon atoms ##STR5## H ______________________________________ PA1 processes for the preparation thereof, chemical intermediates at their preparation, pharmaceutical preparations containing them, and their medicinal use.
新的支气管痉挛松弛活性化合物,具有长效作用和减少不良副作用的结构式##STR1##及其治疗上可接受的盐,其中R选自--C(CH.sub.3).sub.3,##STR2##R.sup.1选自H和R.sup.2,R.sup.2代表公式##STR3##中的基团,其中R.sup.3选自(a)H(b)含1-3个碳原子的烷基基团##STR4##其中R.sup.5选自(e)OH(b)含1-3个碳原子的烷氧基团,而R.sup.4选自(a)H(b)含1-3个碳原子的烷基基团,但须满足R.sup.3和R.sup.4的组合如下: ______________________________________ 当R.sup.3时,R.sup.4为 ______________________________________ H H 含1-3个碳原子的烷基团 H或含1-3个碳原子的烷基团 ##STR5## H ______________________________________ PA1的制备方法、制备其
化学中间体、含有它们的药物制剂和它们的药用。